

TABLE 1—NADAs FOR WHICH APPROVAL IS VOLUNTARILY WITHDRAWN—Continued

Application No.	Trade name (drug)	Applicant
NADA 095–953 .....	MOORMABOOST TY 4000 Medicated (tylosin phosphate) ..	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 100–689 .....	DIFIL Syrup (diethylcarbamazine citrate) .....	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 100–690 .....	DIFIL Tablets (diethylcarbamazine citrate) .....	Evsco Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310.
NADA 107–957 .....	TYLAN 20 Sulfa-G (tylosin phosphate and sulfamethazine)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 111–069 .....	TYLAN 40 Sulfa-G (tylosin phosphate and sulfamethazine)	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 131–956 .....	TYLAN Sulfa-G (tylosin phosphate and sulfamethazine) .....	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 131–957 .....	TYLAN 40 (tylosin phosphate) .....	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 133–490 .....	Ban-D–Wormer II BANMINTH (pyrantel tartrate) .....	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 140–842 .....	HYGROMIX 2.4 Premix (hygromycin B) .....	ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.
NADA 140–958 .....	EQUIPHEN Paste (phenylbutazone) .....	Luitpold Pharmaceuticals, Inc., Animal Health Division, Shirley, NY 11967.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADAs 014–485, 032–322, 044–655, 045–288, 049–890, 055–034, 055–052, 065–158, 065–259, 065–488, 095–953, 100–689, 100–690, 107–957, 111–069, 131–956, 131–957, 133–490, 140–842, and 140–958, and all supplements and amendments thereto, is hereby withdrawn, effective February 13, 2012.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the withdrawal of approval of these applications.

Dated: January 26, 2012.

**Bernadette Dunham,**  
*Director, Center for Veterinary Medicine.*

[FR Doc. 2012–2109 Filed 1–31–12; 8:45 am]

**BILLING CODE 4160–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel; Perinatal HIV-Infected Youth.

*Date:* February 22, 2012.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Rita Anand, Ph.D., Scientific Review Officer Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01 Bethesda, MD 20892, (301) 496–1487, [anandr@mail.nih.gov](mailto:anandr@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: January 24, 2012.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2012–2189 Filed 1–31–12; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* National Cancer Institute Director's Consumer Liaison Group, DCLG Meeting.

*Date:* February 29–March 1, 2012.

*Time:* 9 a.m. to 1 p.m.

*Agenda:* 2/29—Drug Shortage—A Critical Challenge for the Cancer Community; Cancer Drug Shortages: Economic, Regulatory, and Manufacturing Issues; The Role of the Cancer Advocacy Community 3/01—Advocate Engagement at the National Cancer Institute.

*Place:* National Institutes of Health, Building 16, 1st Floor, 16 Center Drive, Bethesda, MD 20892.

*Contact Person:* Amy Bulman, Acting Director, Office of Advocacy Relations, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 10A30, Bethesda, MD 20892, 301–496–9723.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the